Skip to main content
Figure 2 | Respiratory Research

Figure 2

From: A novel small molecule target in human airway smooth muscle for potential treatment of obstructive lung diseases: a staged high-throughput biophysical screening

Figure 2

Testing functional efficacy of small molecules with magnetic twisting cytometry. A and B. The steady-state, stiffness prior to (baseline, open bars) and after the respective cell treatment (closed bars). Human ASM cells were treated for 10 min with (A) relaxing agonists (10 μM isoproterenol or 1 mM db-cAMP) and (B) buffer blank (0.1%, 0.5% or 2% w/v cyclodextrin). Stiffness is expressed as Pascal per nm (Pa/nm). Data are presented by geometric means, and error bars indicate standard error (SE); * indicates P < 0.001 and # indicates P < 0.05 from respective baseline stiffness (n = 152 to 442 cells). C and D. Stiffness responses of human ASM cells. Human ASM cells were (C) treated with vehicle control (0.5% w/v cyclodextrin) or a number of small molecules (200 μM) belonging to the PRLX24905 scaffold and (D) treated with an increasing concentration of compound 85070. For comparison, stiffness responses to relaxing agonists (10 μM isoproterenol or 1 mM db-cAMP) are shown. Stiffness responses are normalized to respective baseline stiffness of an individual ASM cell. Data are presented by geometric means ± SE (n = 314 to 1024 cells); * indicates P < 0.001 and # indicates P < 0.05 from vehicle control.

Back to article page